Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 5/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.41 |
| ▸ | BCL2 | P10415 | 3/20 | 0.41 |
| ▸ | MGLL | Q99685 | 5/20 | 0.41 |
| ▸ | FAAH | O00519 | 3/20 | 0.38 |
| ▸ | KCNJ6 | P48051 | 2/20 | 0.37 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | RPA1 | P27694 | 1/20 | 0.36 |
| ▸ | CRACR2A | Q9BSW2 | 1/20 | 0.36 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3100058 | 0.82 | MGLL (0.49) | MDM2MCL1BCL2MGLLFAAH | |
| SCHEMBL13993243 | 0.80 | MGLL (0.53) | MDM2MCL1BCL2MGLLFAAH | |
| SCHEMBL3109291 | 0.74 | MGLL (0.58) | MDM2MCL1BCL2MGLLKCNJ6 | |
| SCHEMBL3100073 | 0.73 | MDM2 (0.56) | MDM2MCL1BCL2MGLLFAAH | |
| SCHEMBL3099562 | 0.72 | MGLL (0.56) | MDM2MGLLFAAHKCNJ6KCNJ3 | |
| SCHEMBL3100698 | 0.72 | MGLL (0.55) | MGLLFAAH | |
| SCHEMBL13158575 | 0.72 | MGLL (0.54) | MGLLFAAH | |
| SCHEMBL3096845 | 0.72 | MGLL (0.55) | MDM2MCL1BCL2MGLLKCNJ6 | |
| SCHEMBL3098084 | 0.72 | MGLL (0.55) | MDM2MCL1BCL2MGLLKCNJ6 | |
| SCHEMBL3093698 | 0.72 | MGLL (0.55) | MGLLRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | TORAY INDUSTRIES, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2009006-A1 | UREIDE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | TORAY INDUSTRIES, INC. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | UROD, UTS2R, SLC14A1 | MDM2 3246/4885MCL1 4635/4885BCL2 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.